Metropolitan Life Insurance Company (MetLife)’s Organogenesis Holdings ORGO Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ORGO Stock Details ORGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,630	Closed	-$4.63K	–	1481
2024 Q1	$4.63K	Sell	1,630 -2,331	-59%	-$7.92K	﹤0.01%	2250
2023 Q4	$16.2K	Hold	3,961	–	–	﹤0.01%	2004
2023 Q3	$12.6K	Hold	3,961	–	–	﹤0.01%	2113
2023 Q2	$13.2K	Buy	+3,961	New	+$11.7K	﹤0.01%	2150
2023 Q1	–	Sell	-4,331	Closed	-$11.7K	–	2422
2022 Q4	$11.7K	Hold	4,331	–	–	﹤0.01%	2236
2022 Q3	$14K	Buy	4,331 +1,800	+71%	+$8.13K	﹤0.01%	2182
2022 Q2	$12.4K	Sell	2,531 -2,113	-45%	-$13K	﹤0.01%	2260
2022 Q1	$35.4K	Sell	4,644 -6,122	-57%	-$47.4K	﹤0.01%	1789
2021 Q4	$99.5K	Sell	10,766 -514	-5%	-$5.46K	﹤0.01%	2487
2021 Q3	$161K	Buy	+11,280	New	+$175K	﹤0.01%	2247
2021 Q2	–	Sell	-7,752	Closed	-$141K	–	2828
2021 Q1	$141K	Buy	+7,752	New	+$105K	﹤0.01%	2248

Other funds holding ORGO

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ORGO Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Organogenesis Holdings (ORGO) in Q2 2024, closing a stake of 1,630 shares — an estimated $4.63K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ORGO in Q1 2021 and held it in 11 quarters. The position peaked at $161K in Q3 2021. 115 funds tracked by Wall St. Rank hold ORGO as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Organogenesis Holdings position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,630 Organogenesis Holdings shares in Q2 2024, an estimated $4.63K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Organogenesis Holdings in Q1 2021 and held it in 11 quarters.
Metropolitan Life Insurance Company (MetLife)'s Organogenesis Holdings position peaked at $161K in Q3 2021.
115 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.